

**OWL Metabolomics will be presenting new data related to innovations in NASH and NAFLD non-invasive diagnosis in clinical practice and the subtyping of NAFLD severity through metabolomics at the upcoming AASLD Liver Meeting® 2016.**

**Bilbao (Spain), Press Release, October 20, 2016** – One Way Liver S.L. (OWL Metabolomics), a leader in the field of metabolomics focused on development of innovative diagnostic tests for common liver diseases like NASH and NAFLD, today announced upcoming data presentations at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which will be held at the John B. Hynes Convention Center (Boston) from November 11th to 15th.

OWL's latest presentations will consist on an oral communication and two scientific posters. Communication will report:

1. Application of liquid biopsy via metabolomics for patient risk-stratification in NAFLD management, including assessment of steatosis severity;
2. Differentiation of the presence of NAFL or NASH;
3. Use of OWL's proprietary liquid biopsy to identify the presence of initial or advanced liver fibrosis (staging).

The abstract presentations will focus on the clinical validation of commercially-available NASH/NAFLD noninvasive liquid assays; and the discovery of distinct metabolomics-based serum signatures for the subtyping of NASH and for establishing the onset and progression of NAFLD.



Specific OWL presentations include:

### **1 Oral Presentation:**

Sunday, November 13<sup>th</sup>, 1:15 pm-2:45 pm

Parallel D (Session 5): NAFLD: Diagnosis and Natural History

**Title: Metabolomics in a liquid biopsy provides a noninvasive comprehensive NAFLD-diagnostic tool**

### **2 Posters:**

Saturday, November 12<sup>th</sup>, 2:00pm-7:30 m

Session: Steatohepatitis: Clinical and Therapeutic

**Title: A non-invasive lipidomic test accurately discriminates NASH from steatosis and tracks evolution of the disease**

Sunday, November 13<sup>th</sup>, 8:00am-5:30pm

Session: Steatohepatitis: Experimental II

**Title: Metabolomic classification of murine and human nonalcoholic fatty liver disease**

### **OWL Commercial Exhibit during AASLD:**

OWL Metabolomics will also be present at AASLD with a corporate display in the commercial exhibit space. Please plan on visiting OWL in **Booth #638** during The Liver Meeting.

OWL is pleased to arrange for you a detailed scientific discussion anytime during the Liver Meeting. If you or your team are interested in such a meeting, please contact Ms. Miriam Pérez ([mperez@owlmetabolomics.com](mailto:mperez@owlmetabolomics.com)) to arrange for a specific meeting time.



## About OWL Metabolomics

OWL Metabolomics is a biotechnology company committed to the identification, validation and global commercialization of novel diagnostic assays for the liver and other prevalent human diseases, including the identification of potential therapeutic targets involved in the development of such diseases. Since its inception in 2002, OWL has pioneered unique diagnostic research within the fatty liver space, a field of considerable focus in new drug development.

The 'OWLiver' and 'OWLiver Care' assays are the world's first metabolomics-based in-vitro tests for diagnosing NASH and hepatic steatosis (NAFLD), respectively, using micro-blood samples (<0.2 ml) versus today's diagnostic gold-standard which mandates an invasive liver biopsy.

OWL Metabolomics is a privately-held company based in Derio, Spain. Its main partner is the venture capital management firm Cross Road Biotech Inversiones Biotecnológicas. OWL Metabolomics collaborates globally with hospitals, liver research centers, biotechnology groups and the pharmaceutical industry.

<http://www.owlmetabolomics.com/liver-disease-diagnosis.aspx>

### Contact

One Way Liver, S.L.  
Parque Tecnológico de Bizkaia  
502 Building  
48160 Derio, Spain  
Phone: +34 94 431 85 40

